The University of Calgary and Providence Therapeutics have partnered to research potential treatments in infectious diseases, oncology, and veterinary medicine. The “UCalgary And Providence Therapeutics United for translational Research Excellence” (CAPTURE) program will see UCalgary researchers identify candidate diseases for treatment production using Providence’s mRNA platform. “Building on our successful collaboration in serious late-stage cancers, we hope that, by formalizing this partnership at an institutional level, Providence and UCalgary will continue to drive early access to cutting-edge breakthroughs in a range of disease settings,” said Providence Therapeutics CEO Brad Sorenson.
UCalgary
